The addition of retifanlimab to chemotherapy increased progression-free survival in patients with advanced squamous cell ...

Paolo Tarantino, MD, PhD, explains that the chemotherapy-related toxicities from an ADC are more likely to limit dosage for ...

Panelists discuss how a 48-year-old fitness instructor with ALK-rearranged stage IV lung cancer and bone metastases was ...

While CIML natural killer immunotherapy can result in infection-like reactions, required prior chemo may cause infections, ...

Patients receiving subcutaneous daratumumab have less chair time and premedication than those receiving IV formulation, says ...

Panelists discuss updated MonumenTAL-1 trial data demonstrating high response rates and prolonged survival with ...

Panelists discuss how patients newly diagnosed with multiple myeloma often face emotional and informational overload, but ...

Panelists discuss updated safety findings from GPRC5D-targeted bispecific therapy in relapsed/refractory multiple myeloma, ...

Panelists discuss how patient portal use improves communication by allowing patients to report adverse effects with photos ...

Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the ...

Panelists discuss the evolving role of bispecific antibodies in relapsed/refractory multiple myeloma, emphasizing their value ...

Panelists discuss how the COCOON study’s advanced dermatologic prophylaxis protocol, including systemic antibiotics and ...